Literature DB >> 18379936

Clinical and investigative profile of biopsy-proven sarcoid uveitis in India.

Sudha K Ganesh1, Manisha Agarwal.   

Abstract

PURPOSE: Retrospective analysis of the clinical features, investigative profile, response to treatment, and final visual outcome in histopathologically confirmed cases of sarcoid uveitis.
METHODS: Retrospective case series analysis was done of 15 eyes of 9 patients seen between July 1999 and August 2003 with biopsy-proven sarcoid uveitis. There were 3 were males and 6 females. The mean age at presentation was 44.1 years (range 11-62 years), The mean follow-up was 28.4 months.
RESULTS: Six patients had bilateral ocular involvement and 3 had unilateral involvement. Five out of 9 patients had primarily ocular involvement. The most common presentation was intermediate uveitis and granulomatous anterior uveitis in 7 patients. Eight of 9 patients responded well to the medical treatment with systemic and periocular steroids.
CONCLUSIONS: Ocular lesions can be the primary manifestation of systemic sarcoidosis. Sarcoid uveitis in the Asian Indian population often presents an intermediate uveitis with granulomatous anterior uveitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379936     DOI: 10.1080/09273940801904150

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  3 in total

Review 1.  Intermediate uveitis.

Authors:  B Manohar Babu; S R Rathinam
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

Review 2.  Current approach in the diagnosis and management of panuveitis.

Authors:  Reema Bansal; Vishali Gupta; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

3.  Prevalence, clinical profile, investigations, and visual outcome of sarcoid intermediate uveitis in a tertiary eye care center in South India.

Authors:  Jeyasooriya Ramdoss; Anupreeti Jain; G N Thejesvi; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.